| Document |
Document Title |
|
WO/2021/106988A1 |
It was found that a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has potent G9a inhibitory activity. Because of the ability to inhibit G9a, the compound (I) or a pharmaceutically acceptable sa...
|
|
WO/2021/107117A1 |
A method for producing a hematopoietic cell from a pluripotent stem cell, the method including a first step for culturing naïve pluripotent stem cells and inducing differentiation into yolk sac cells, a second step for culturing primed ...
|
|
WO/2021/105389A1 |
Antibodies to the enzyme matriptase‐2 (MTP‐2) are presented. Inhibiting MTP‐2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine pr...
|
|
WO/2021/107835A1 |
The present invention provides an oral pharmaceutical composition comprising iron succinate for use in treating iron deficiency in a subject diagnosed with heart failure (HF) with reduced ejection fraction (HFrEF), and a method for treat...
|
|
WO/2021/108806A1 |
Compositions, containers and kits for low temperature storage of a specified quantity of packed red blood cells (RBCs) include L-camitine, HES and blood plasma proteins. Methods of storing a packed RBC blood product, transfusing a packed...
|
|
WO/2021/105137A1 |
Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolys...
|
|
WO/2021/098826A1 |
Use of albiflorin, paeoniflorin or a composition containing albiflorin or paeoniflorin in the preparation of drugs, healthcare products, food nutritional agents or food additives for increasing endogenous erythropoietin; and use of albif...
|
|
WO/2021/098817A1 |
Provided are a dioxopiperazine derivative, a preparation method therefor and pharmaceutical use thereof. In particular, provided are compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The ...
|
|
WO/2021/101910A1 |
Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients also having severe hepatic impairment. Also provided herein are methods for administering voxelotor and avoiding or lessening adverse dru...
|
|
WO/2021/098701A1 |
The present invention relates to the field of food and drugs, specifically to a use of a Malus niedzwetskyana product for inhibiting blood clot formation. The Malus niedzwetskyana product comprises a drug, a regular food product or a hea...
|
|
WO/2021/102326A1 |
This disclosure relates to treatments for reducing the side effects associated with treatment of a medication or drug, such as a chemotherapy medication, being experienced by a patient. This may be accomplished by administering to a pati...
|
|
WO/2021/098692A1 |
An application of a cherry plum product in inhibiting thrombosi. The cherry plum product comprises: jam, dried fruit, fruit preserves, fruit juice, fruit powder, fruit wine, candy, pastry, oral liquid, and fresh cherry plum fruit. The ch...
|
|
WO/2021/099616A1 |
The present invention relates to a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sic...
|
|
WO/2021/101278A1 |
The present invention provides: a functional microscaffold that can be magnetically actuated for effective targeted-treatment of intractable diseases; and a manufacturing method therefor. A functional microscaffold that can be magnetical...
|
|
WO/2021/102258A1 |
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
|
|
WO/2021/100031A1 |
Provided is a drug used for the treatment or prevention of cerebral hemorrhage, the drug containing, as active ingredients: the compound of formula (I) or a medically acceptable salt thereof; and an ester or a solvate. 74
|
|
WO/2021/094208A1 |
The invention relates to substituted imidazo pyrimidine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular di...
|
|
WO/2021/095775A1 |
[Problem] The purpose of the present invention is to provide a plant-derived component useful as an antiplasmin agent. [Solution] An antiplasmin agent including an extract of a plant of the family Labiatae, genus Scutellaria; family Zing...
|
|
WO/2021/094209A1 |
The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in p...
|
|
WO/2021/097305A1 |
Compositions, systems and methods for delivering CRISPR/Cas9-based genome editing system and a donor protein to a cell.
|
|
WO/2021/097157A1 |
Provided herein are compositions and methods for treating a Cl esterase inhibitor deficiency by normalizing levels of the Cl esterase inhibitor protein in a subject having HAE.
|
|
WO/2021/097350A1 |
The present disclosure provides methods and compositions for genetically modifying hematopoietic stem and progenitor cells (HSPCs), in particular by replacing the HBA1 or HBA2 locus in the HSPCs with a transgene encoding a therapeutic pr...
|
|
WO/2021/095945A1 |
The present invention relates to a use of a pharmaceutical composition for treating stroke or sequelae following stroke, the composition comprising a phosphodiesterase type 5 activity inhibitor and a Rho-associasted kinase (ROCK) inhibit...
|
|
WO/2021/095980A1 |
A Sikchijeho-tang composition of the present invention exhibits a blood circulation-enhancing effect as high as or higher than that of Gagamjeho-tang comprising a smoky Prunus mume fruit, a Amomum villosum LOUR. fruit, an Amomum tsao-ko ...
|
|
WO/2021/097326A1 |
Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compoun...
|
|
WO/2021/094210A1 |
The invention relates to substituted pyrazine carboxamide derivatives of formula (I) and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in particular...
|
|
WO/2021/096927A1 |
Disclosed herein are compositions and methods for treating pulmonary hypertension whereby a SCUBE1 polynucleotide or polypeptide is administered. Also disclosed herein are methods for diagnosing and/or prognosing pulmonary arterial hyper...
|
|
WO/2021/092227A1 |
Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozyg...
|
|
WO/2021/091846A1 |
The present disclosure relates to the use of Compound (I) or a pharmaceutically acceptable salt thereof, for the treatment of mast cell diseases and eosinophilic disorders.
|
|
WO/2021/091532A1 |
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5
-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
|
|
WO/2021/090594A1 |
A purpose of the present invention is to produce neutrophil-like cells in numbers that can be used in granulocyte transfusion therapy. It became possible to vastly improve proliferation by further forcibly expressing at least one gene be...
|
|
WO/2021/092485A1 |
The present invention features compositions and methods useful in inhibiting the expression of NFIX within a cell and thereby treating patients suffering from a hemoglobinopathy such as sickle cell disease or β-thalassemia. The present ...
|
|
WO/2021/085504A1 |
Provided are a B-cell antibody receptor (BAR), a BAR-T cell and others which are effective for the treatment of diseases associated with antibodies produced in the bodies of patients. The B-cell antibody receptor (BAR) according to the p...
|
|
WO/2021/081581A1 |
The present invention relates to antigen binding proteins comprising an antigen binding domain that binds to plasminogen, wherein the antigen binding protein reduces the activation of plasminogen to plasmin, pharmaceutical compositions c...
|
|
WO/2021/086097A1 |
The present invention relates to a powder-type hemostatic composition and a preparation method therefor and, more specifically, to a powder aggregate obtained by binding biocompatible hemostatic material powders with a binder and having ...
|
|
WO/2021/087177A1 |
Embodiments of the disclosure encompass methods and compositions related to overcoming or preventing cancer resistance to anti-apoptotic proteins, for example BH3 mimetics. The disclosure provides methods for modulating p73 to reduce can...
|
|
WO/2021/083383A1 |
Disclosed are a nitrogen-containing fused cyclic compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereomer, a tautomer, a solvate, a polymorph, or a prodrug thereof, and a ...
|
|
WO/2021/085575A1 |
[Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercise and behaviors associated with impact such as striking, for example, as when continually hitting the so...
|
|
WO/2021/081582A1 |
The present invention provides an antigen binding protein comprising an antigen binding domain that binds to plasmin, wherein the antigen binding protein reduces the activity of plasmin. The invention also provides compositions comprisin...
|
|
WO/2021/083073A1 |
The present invention provides a product for treating a hepatocyte Alb gene-based disease, comprising a reagent capable of inserting a target gene into intron 13 of Alb in hepatocytes and co-expressing the target gene and Alb. The diseas...
|
|
WO/2021/087144A1 |
This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1), including methods suitable for conversion, correction, and maintenance therapy for patients. For exa...
|
|
WO/2021/087050A1 |
The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation th...
|
|
WO/2021/078889A1 |
The invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof for the use in the treatment of sickle cell disease and for the use in preventing and treating vascular inflammation and vaso-occlusion.
|
|
WO/2021/081277A1 |
The present invention provides dosing regimens of anti-C5 antibodies, such as pozelimab, for treating or preventing CS-associated diseases such as paroxysmal nocturnal hemoglobinuria or CHAPLE disease.
|
|
WO/2021/080359A1 |
The present invention relates to a 6-6 bicyclic ring-containing compound derivative and use thereof. The compound according to the present invention acts as a PRMT5 inhibitor, and thus can be effectively used in the prevention or treatme...
|
|
WO/2021/080262A1 |
The present invention relates to an "intravascular thrombus" lytic agent and, more specifically, to a polypeptide, a gene, and a pharmaceutical composition comprising same, wherein the polypeptide is composed of a thrombo-recognition dom...
|
|
WO/2021/078076A1 |
A novel crystalline form of acetylated eltrombopag and a preparation method thereof belonging to the field of medicinal chemistry. The crystalline form has good stability and facilitates operations in storage, transfer, and production pr...
|
|
WO/2021/079536A1 |
This composition for lysis of Staphylococcus aureus or this composition for prevention or therapy of diseases caused by Staphylococcus aureus contains as active ingredients: at least one bacteriophage selected from the group consisting o...
|
|
WO/2021/079978A1 |
The present invention addresses the problem of providing a therapeutic or prophylactic agent that is for cachexia and that exhibits significant efficacy in therapy of cachexia with few side effects. The present invention provides a thera...
|
|
WO/2021/079986A1 |
A composition for lysing Staphylococcus aureus or a composition for preventing or treating a disease caused by Staphylococcus aureus, said composition comprising, as active ingredients, at least one bacteriophage selected from the group ...
|
